Document ZJNyNjroo52qeE8nnygKxXopL

Meetingwith 0st on REACH eision and Chemicl Strategyfor Sutanably oT ES HO I SS TLE oi Reformulate products: L'Oral explainedthat cosmeticsare very complex products and + Mixture AssessmentFactor (MAF): L'Oral asked whiastt he Commission's approach on MAF. AT CHT EE Generic Risk Approach: GROW explained that GRA will not applied at once but it will take some. years before EIF and it will be subject to a decision-making process and related consultations of stakeholders. * Derogations from GRA: L'0ral explained that Article 15 in the CPR is notan exemption but a derogation supported by data on the lack of alternatives and safe use. GROW explained that an equivalent procedure to Article 15 will not be possible under GRA. The "safe use" derogations (in general) is being discussed but no decision yet on whether it will be possible or under which conditions, and if both for human health and environmental impacts. Next: L'Oral is meeting Cssr Breton on 15 October